1290629-80-9

Upstream product

• 1125-88-8 benzaldehyde dimethyl acetal 
• 1290629-79-6 [(2R,3R,4R,5S,6S)-3,4,5-trisbenzyloxy-6-[4-chloro-3-[(4-ethoxyphenyl)methyl]benzenyl]tetrahydropyran-2-yl]methanol 
• 1290629-78-5 (2S,3S,4R,5R,6R)-3,4,5-tris-benzyloxy-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-trityloxymethyl-tetrahydro-pyran 
• 1290629-77-4 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-trityloxymethyl-tetrahydro-pyran-3,4,5-triol 
• 461432-26-8 dapagliflozin 

Downstream Products

• 1290629-81-0 [(3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-2-(hydroxymethyl)tetrahydropyran-2-yl]methanol 
• 1290630-09-9 {(3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-hydroxymethyl-tetrahydro-pyran-2-yl}-methanol bis-tosylate 
• 1290630-10-2 {(3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-methyl-tetrahydro-pyran-2-yl}-methanol 
• 1290630-11-3 (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-hydroxymethyl-2-methyl-tetrahydro-pyran-3,4,5-triol 
• 1290630-15-7 toluene-4-sulfonic acid (3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-hydroxymethyl-tetrahydro-pyran-2-ylmethyl ester 
• 1290630-16-8 (6S,7S,8R,9S)-7,8,9-tris-benzyloxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,5-dioxa-spiro[3.5]nonane 
• 1221496-17-8 (6S,7R,8R,9S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,5-dioxa-spiro[3.5]nonane-7,8,9-triol 
• 1290629-82-1 (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,2-bis-hydroxymethyl-tetrahydro-pyran-3,4,5-triol 
• 1290629-83-2 (3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,2-bis-iodomethyl-tetrahydro-pyran 
• 1290629-84-3 (3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,2-dimethyl-tetrahydro-pyran 
• 1290629-85-4 (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,2-dimethyl-tetrahydro-pyran-3,4,5-triol 

Relevant academic research and scientific papers

Glucopyranosyl derivative, its preparation process and its use in medicine

Disclosed are a substituted pyranol derivative with sodium dependent glucose transporters (SGLTs) inhibitor compound 4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl, a preparation method thereof, and a pharmaceutical application thereof; and particularly a pyranol derivative expressed in formula I, a pharmaceutically acceptable salt thereof or all stereo isomers thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative as well as application thereof in treating diabetes and diabetes related diseases. The definitions of the substituent groups in formula I are the same as the definitions in the specification.

Glucopyranosyl derivative, its preparation process and its use in medicine

The invention relates to a C-aryl substituted glucopyranosyl derivative as an inhibitor of sodium dependent glucose transporter (SGLTs), the preparation method and the medical use thereof, in particular the glucopyranosyl derivative shown as general formula (I) or pharmaceutically acceptable salts or all stereoisomers thereof, the preparation method or pharmaceutical compositions containing the derivative and the use for treating diabetes and related diseases, wherein the definition of each substituent in general formula (I) is the same as that in the description.

GLYCOSIDE DERIVATIVE AND USES THEREOF

This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.